Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
bioAffinity Technologies, Inc. (BIAF)
USD0.72
+0.01 (+1.49%)
US NASDAQ Healthcare Medical - Diagnostics & Research
Address
22211 West Interstate 10 78257
San Antonio, TX, US
San Antonio, TX, US
CEO
Maria Zannes
Website
bioaffinitytech.com
IPO
2022-09-01
CIK 1712762 ISIN US09076W3079
Also trades on
NASDAQ Capital Market · BIAF (USD)
NASDAQ Global Select · BIAFW (USD)
Description
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
News Sentiment (7d)
Based on only 2 articles — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.72
+0.01 (+1.49%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
629.7K
Beta
-1.34
Float Shares
4.35M
Free Float %
96.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.57% | -3.09% | -43.88% | +70.91% | -12.56% | +59.32% | -68.67% | -96.61% | -99.24% | -99.24% | -99.24% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Hold
Price Targets & DCF
Current price
0.72
Ratings Trend (MoM)
0% Bullish
| Rating | 2025-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-17.12
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%-34.2% Q1'26: -27.1% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+61.5% ★ Q1'26: +83.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-156.2% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-171.6% Q1'26: -267.6% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%-531.6% Q1'26: -743.6% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%+325.7% Q1'26: +729.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-0.12× Q1'26: -0.10× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|
| Revenue |
2.53M
est: 2.10M (+20.6%)
|
9.36M
est: 9.57M (-2.2%)
|
6.16M
est: 6.09M (+1.2%)
|
7.31M
7.31M – 7.31M
+20.0% YoY
|
| EBITDA |
-7.63M
est: -373.7K (-1,941.5%)
|
-8.33M
est: -5.53M (-50.6%)
|
-10.07M
est: -3.52M (-186.2%)
|
-4.22M
-4.22M – -4.22M
-20.0% YoY
|
| EBIT |
-7.88M
est: -400.9K (-1,865.5%)
|
-8.94M
est: -5.66M (-58.0%)
|
-10.57M
est: -3.60M (-193.9%)
|
-4.32M
-4.32M – -4.32M
-20.0% YoY
|
| Net Income |
-7.94M
est: -10.19M (+22.1%)
|
-9.04M
est: -35.63M (+74.6%)
|
-14.91M
est: -24.78M (+39.8%)
|
-13.94M
-13.94M – -13.94M
+43.8% YoY
|
| SGA |
6.79M
est: 219.37M (-96.9%)
|
9.94M
est: 1.00B (-99.0%)
|
9.91M
est: 636.60M (-98.4%)
|
764.19M
764.19M – 764.19M
+20.0% YoY
|
| EPS |
-27.30
est: -25.20 (-8.3%)
|
-22.50
est: -20.70 (-8.7%)
|
-8.66
est: -14.40 (+39.9%)
|
-8.10
-8.10 – -8.10
+43.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-01 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-11.76M
OE per share TTM
-8.58
Owner's Yield
-132.86%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
28.4%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
1
Total invested
4.2K
Insider transactions (90d)
0
Beneficial owners (>5%)
2
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Roby P. Joyce | 603.1K | 6.44% | — | — | — | 603.1K | IN | United States of America | 2023-10-10 | ↗ |
| 2 | The Joyce Living Trust | 603.1K | 6.44% | — | — | — | 603.1K | OO | United States of America | 2023-10-10 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q3
Investors holding
1
-16 vs prev Q
New positions
0
Closed positions
16
Increased
0
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | IFP ADVISORS, INC | — -25.0K (-100.0%) | — -4.2K (-100.0%) | 0.00% -3.122 pp | 0.00% 0.000 pp | USD— | 9 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 90.7K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
100.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+100,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-12 | Rios Roberto | Director | — | — | Common Stock | 0 | 0.00 | — | 833 | D | ↗ |
| 2025-08-12 | Oppenheimer John J. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-01-10 | Zannes Timothy P | Officer | A-Award | A | Common Stock | 8,641 | 0.00 | — | 54,765 | D | ↗ |
| 2025-01-10 | Zannes Maria | Director / Officer | A-Award | A | Common Stock | 37,037 | 0.00 | — | 280,359 | D | ↗ |
| 2025-01-10 | Reveles Xavier Trinidad | Officer | A-Award | A | Common Stock | 21,604 | 0.00 | — | 41,943 | D | ↗ |
| 2025-01-10 | GIRGENTI STEVEN | Director / Officer | A-Award | A | Common Stock | 14,814 | 0.00 | — | 1,080,062 | D | ↗ |
| 2025-01-10 | Edwards James Michael | Officer | A-Award | A | Common Stock | 6,172 | 0.00 | — | 120,128 | D | ↗ |
| 2024-11-05 | Edwards James Michael | Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 113,956 | D | ↗ |
| 2024-09-16 | Edwards James Michael | Officer | — | — | Common Stock, par value $0.007 | 0 | 0.00 | — | 13,956 | D | ↗ |
| 2024-07-01 | Zannes Maria | Director / Officer | A-Award | A | Common Stock | 33,784 | 0.00 | — | 243,322 | — | ↗ |
| 2024-07-01 | Rubin Gary D | Director / 10% Owner | A-Award | A | Common Stock | 33,784 | 0.00 | — | 146,597 | — | ↗ |
| 2024-07-01 | Platt Jamie | Director | A-Award | A | Common Stock | 33,784 | 0.00 | — | 54,748 | — | ↗ |
| 2024-07-01 | KNIGHT PETER S | Director | A-Award | A | Common Stock | 33,784 | 0.00 | — | 117,455 | — | ↗ |
| 2024-07-01 | Joyce Roby | Director | A-Award | A | Common Stock | 33,784 | 0.00 | — | 66,615 | — | ↗ |
| 2024-07-01 | GIRGENTI STEVEN | Director / Officer | A-Award | A | Common Stock | 33,784 | 0.00 | — | 1,065,248 | — | ↗ |
| 2024-07-01 | DIAMOND STUART | Director | A-Award | A | Common Stock | 33,784 | 0.00 | — | 99,088 | — | ↗ |
| 2024-07-01 | Anderson Robert A. | Director | A-Award | A | Common Stock | 33,784 | 0.00 | — | 163,936 | — | ↗ |
| 2024-06-12 | Zannes Maria | Director / Officer | A-Award | A | Common Stock | 8,296 | 0.00 | — | 209,538 | — | ↗ |
| 2024-06-12 | Rubin Gary D | Director / 10% Owner | A-Award | A | Common Stock | 8,296 | 0.00 | — | 112,813 | — | ↗ |
| 2024-06-12 | Platt Jamie | Director | A-Award | A | Common Stock | 8,296 | 0.00 | — | 20,964 | — | ↗ |
| 2024-06-12 | KNIGHT PETER S | Director | A-Award | A | Common Stock | 8,296 | 0.00 | — | 83,671 | — | ↗ |
| 2024-06-12 | Joyce Roby | Director | A-Award | A | Common Stock | 8,296 | 0.00 | — | 32,831 | — | ↗ |
| 2024-06-12 | GIRGENTI STEVEN | Director / Officer | A-Award | A | Common Stock | 8,296 | 0.00 | — | 1,031,464 | — | ↗ |
| 2024-06-12 | DIAMOND STUART | Director | A-Award | A | Common Stock | 8,296 | 0.00 | — | 65,304 | — | ↗ |
| 2024-06-12 | Anderson Robert A. | Director | A-Award | A | Common Stock | 8,296 | 0.00 | — | 130,152 | — | ↗ |
| 2024-04-08 | Zannes Maria | Officer | M-Exempt | A | Common Stock | 64,848 | 1.16 | 75.2K | 229,506 | — | ↗ |
| 2024-04-04 | Zannes Timothy P | Officer | M-Exempt | A | Common Stock | 64,848 | 1.16 | 75.2K | 75,155 | — | ↗ |
| 2024-04-03 | GIRGENTI STEVEN | Director | M-Exempt | A | Common Stock | 64,848 | 1.16 | 75.2K | 1,056,606 | — | ↗ |
| 2024-02-26 | Anderson Robert A. | Director | M-Exempt | A | Common Stock | 64,848 | 1.16 | 74.9K | 121,856 | — | ↗ |
| 2024-02-16 | GIRGENTI STEVEN | Director / Officer | A-Award | A | Common Stock | 39,474 | 1.52 | 60.0K | 991,758 | — | ↗ |
| 2024-01-31 | Zannes Timothy P | Officer | A-Award | A | Common Stock | 6,688 | 0.00 | — | 10,307 | — | ↗ |
| 2024-01-31 | Zannes Maria | Director / Officer | A-Award | A | Common Stock | 23,885 | 0.00 | — | 164,658 | — | ↗ |
| 2024-01-31 | Reveles Xavier Trinidad | Officer | A-Award | A | Common Stock | 16,720 | 0.00 | — | 20,339 | — | ↗ |
| 2024-01-31 | Rebel Vivienne I | Officer | A-Award | A | Common Stock | 31,847 | 0.00 | — | 46,228 | — | ↗ |
| 2024-01-31 | GIRGENTI STEVEN | Director / Officer | A-Award | A | Common Stock | 11,943 | 0.00 | — | 952,284 | — | ↗ |
| 2024-01-31 | Dougherty Michael Philip | Officer | A-Award | A | Common Stock | 31,847 | 0.00 | — | 84,203 | — | ↗ |
| 2024-01-01 | Zannes Maria | Director / Officer | A-Award | A | Common Stock | 12,668 | 1.48 | 18.7K | 140,773 | — | ↗ |
| 2024-01-01 | Rubin Gary D | Director / 10% Owner | A-Award | A | Common Stock | 12,668 | 1.48 | 18.7K | 104,517 | — | ↗ |
| 2024-01-01 | Platt Jamie | Director | A-Award | A | Common Stock | 12,668 | 1.48 | 18.7K | 12,668 | — | ↗ |
| 2024-01-01 | KNIGHT PETER S | Director | A-Award | A | Common Stock | 12,668 | 1.48 | 18.7K | 75,375 | — | ↗ |
| 2024-01-01 | Joyce Roby | Director | A-Award | A | Common Stock | 12,668 | 1.48 | 18.7K | 24,535 | — | ↗ |
| 2024-01-01 | GIRGENTI STEVEN | Director / Officer | A-Award | A | Common Stock | 12,668 | 1.48 | 18.7K | 940,341 | — | ↗ |
| 2024-01-01 | DIAMOND STUART | Director | A-Award | A | Common Stock | 12,668 | 1.48 | 18.7K | 57,008 | — | ↗ |
| 2024-01-01 | Anderson Robert A. | Director | A-Award | A | Common Stock | 12,668 | 1.48 | 18.7K | 57,008 | — | ↗ |
| 2023-12-01 | Platt Jamie | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-10-01 | Zannes Maria | Director / Officer | A-Award | A | Common Stock | 11,867 | 1.58 | 18.7K | 128,105 | — | ↗ |
| 2023-10-01 | Rubin Gary D | Director / 10% Owner | A-Award | A | Common Stock | 11,867 | 1.58 | 18.7K | 91,849 | — | ↗ |
| 2023-10-01 | Meghji Mohsin Y | Director | A-Award | A | Common Stock | 11,867 | 1.58 | 18.7K | 109,737 | — | ↗ |
| 2023-10-01 | KNIGHT PETER S | Director | A-Award | A | Common Stock | 11,867 | 1.58 | 18.7K | 62,707 | — | ↗ |
| 2023-10-01 | Joyce Roby | Director | A-Award | A | Common Stock | 11,867 | 1.58 | 18.7K | 11,867 | — | ↗ |
| 2023-10-01 | GIRGENTI STEVEN | Director / Officer | A-Award | A | Common Stock | 11,867 | 1.58 | 18.7K | 927,673 | — | ↗ |
| 2023-10-01 | DIAMOND STUART | Director | A-Award | A | Common Stock | 11,867 | 1.58 | 18.7K | 44,340 | — | ↗ |
| 2023-10-01 | Anderson Robert A. | Director | A-Award | A | Common Stock | 11,867 | 1.58 | 18.7K | 44,340 | — | ↗ |
| 2023-09-18 | Reveles Xavier Trinidad | Officer | — | D | Common Stock | 0 | 0.00 | — | 3,619 | — | ↗ |
| 2023-09-18 | Joyce Roby | Director | — | I | Common Stock | 0 | 0.00 | — | 583,130 | — | ↗ |
| 2023-08-09 | GIRGENTI STEVEN | Director / Officer | A-Award | A | Common Stock | 26,315 | 2.28 | 60.0K | 915,806 | D | ↗ |
| 2023-07-01 | Zannes Maria | Director / Officer | A-Award | A | Common Stock | 10,245 | 1.83 | 18.7K | 116,238 | — | ↗ |
| 2023-07-01 | Rubin Gary D | Director / 10% Owner | A-Award | A | Common Stock | 10,245 | 1.83 | 18.7K | 79,982 | — | ↗ |
| 2023-07-01 | Meghji Mohsin Y | Director | A-Award | A | Common Stock | 10,245 | 1.83 | 18.7K | 97,870 | — | ↗ |
| 2023-07-01 | KNIGHT PETER S | Director | A-Award | A | Common Stock | 10,245 | 1.83 | 18.7K | 50,840 | — | ↗ |
| 2023-07-01 | GIRGENTI STEVEN | Director / Officer | A-Award | A | Common Stock | 10,245 | 1.83 | 18.7K | 889,491 | D | ↗ |
| 2023-07-01 | DIAMOND STUART | Director | A-Award | A | Common Stock | 10,245 | 1.83 | 18.7K | 32,473 | — | ↗ |
| 2023-07-01 | Anderson Robert A. | Director | A-Award | A | Common Stock | 10,245 | 1.83 | 18.7K | 32,473 | — | ↗ |
| 2023-06-06 | Zannes Maria | Director / Officer | A-Award | A | Common Stock | 26,178 | 1.91 | 50.0K | 105,993 | — | ↗ |
| 2023-06-06 | Dougherty Michael Philip | Officer | A-Award | A | Common Stock | 52,356 | 1.91 | 100.0K | 52,356 | — | ↗ |
| 2023-05-01 | Dougherty Michael Philip | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-04-15 | Zannes Maria | Director / Officer | A-Award | A | Common Stock | 9,920 | 1.89 | 18.7K | 79,815 | — | ↗ |
| 2023-04-15 | Rubin Gary D | Director / 10% Owner | A-Award | A | Common Stock | 9,920 | 1.89 | 18.7K | 69,737 | — | ↗ |
| 2023-04-15 | Meghji Mohsin Y | Director | A-Award | A | Common Stock | 9,920 | 1.89 | 18.7K | 87,625 | — | ↗ |
| 2023-04-15 | KNIGHT PETER S | Director | A-Award | A | Common Stock | 9,920 | 1.89 | 18.7K | 40,595 | — | ↗ |
| 2023-04-15 | GIRGENTI STEVEN | Director / Officer | A-Award | A | Common Stock | 9,920 | 1.89 | 18.7K | 879,246 | D | ↗ |
| 2023-04-15 | DIAMOND STUART | Director | A-Award | A | Common Stock | 9,920 | 1.89 | 18.7K | 22,228 | — | ↗ |
| 2023-04-15 | Anderson Robert A. | Director | A-Award | A | Common Stock | 9,920 | 1.89 | 18.7K | 22,228 | — | ↗ |
| 2023-01-01 | Zannes Maria | Director / Officer | A-Award | A | Common Stock | 8,227 | 2.28 | 18.8K | 69,895 | — | ↗ |
| 2023-01-01 | Rubin Gary D | Director / 10% Owner | A-Award | A | Common Stock | 8,227 | 2.28 | 18.8K | 59,817 | — | ↗ |
| 2023-01-01 | Meghji Mohsin Y | Director | A-Award | A | Common Stock | 8,227 | 2.28 | 18.8K | 77,705 | — | ↗ |
| 2023-01-01 | KNIGHT PETER S | Director | A-Award | A | Common Stock | 8,227 | 2.28 | 18.8K | 30,675 | — | ↗ |
| 2023-01-01 | GIRGENTI STEVEN | Director / Officer | A-Award | A | Common Stock | 8,227 | 2.28 | 18.8K | 869,326 | D | ↗ |
| 2023-01-01 | DIAMOND STUART | Director | A-Award | A | Common Stock | 8,227 | 2.28 | 18.8K | 12,308 | — | ↗ |
| 2023-01-01 | Anderson Robert A. | Director | A-Award | A | Common Stock | 8,227 | 2.28 | 18.8K | 12,308 | — | ↗ |
| 2022-11-17 | Zannes Timothy P | Officer | A-Award | A | Common Stock, par value $0.007 | 3,619 | 0.00 | — | 3,619 | — | ↗ |
| 2022-11-17 | Zannes Maria | Officer | A-Award | A | Common Stock | 18,099 | 0.00 | — | 61,668 | — | ↗ |
| 2022-11-17 | Rebel Vivienne I | Officer | A-Award | A | Common Stock, par value $0.007 | 7,239 | 0.00 | — | 14,381 | — | ↗ |
| 2022-11-17 | Edwards James Michael | Officer | A-Award | A | Common Stock, par value $0.007 | 3,619 | 0.00 | — | 36,815 | — | ↗ |
| 2022-09-06 | Zannes Maria | Officer | C-Conversion | D | Unsecured Convertible Promissory Note | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-09-06 | Rubin Gary D | Director / 10% Owner | — | D | Secured Convertible Promissory Note | 15,876 | 4.20 | 66.7K | 0 | — | ↗ |
| 2022-09-06 | Perlmutter Nathan M | 10% Owner | C-Conversion | D | Unsecured Convertible Promissory Note | 0 | 4.20 | — | 0 | — | ↗ |
| 2022-09-06 | Meghji Mohsin Y | Director | C-Conversion | A | Common Stock, par value $0.007 | 40,907 | 3.67 | 150.1K | 69,478 | — | ↗ |
| 2022-09-06 | GIRGENTI STEVEN | Officer | C-Conversion | A | Common Stock | 58,797 | 4.20 | 246.9K | 531,475 | — | ↗ |
| 2022-09-06 | Edwards James Michael | Officer | C-Conversion | A | Common Stock, par value $0.007 | 2,243 | 4.20 | 9.4K | 32,566 | — | ↗ |
| 2022-09-01 | Edwards James Michael | Officer | — | — | Non-tradeable Warrants (right to buy) | 6,120 | 3.06 | 18.7K | 0 | D | ↗ |
| 2022-08-31 | Zannes Maria | Officer | P-Purchase | A | Non-tradeable Warrants (right to buy) | 16,326 | 0.00 | — | 16,326 | — | ↗ |
| 2022-08-31 | Rubin Gary D | Director | P-Purchase | A | Non-tradeable Warrants (right to buy) | 16,326 | 0.00 | — | 16,326 | — | ↗ |
| 2022-08-31 | KNIGHT PETER S | Director | P-Purchase | A | Non-tradeable Warrants (right to buy) | 8,163 | 0.00 | — | 8,163 | — | ↗ |
| 2022-08-31 | GIRGENTI STEVEN | Officer | P-Purchase | A | Non-tradeable Warrants (right to buy) | 40,916 | 0.00 | — | 40,916 | — | ↗ |
| 2022-08-31 | DIAMOND STUART | Director | P-Purchase | A | Non-tradeable Warrants (right to buy) | 4,081 | 0.00 | — | 4,081 | — | ↗ |
| 2022-08-31 | Anderson Robert A. | Director | P-Purchase | A | Non-tradeable Warrants (right to buy) | 4,081 | 0.00 | — | 4,081 | — | ↗ |
| 2022-08-29 | Zannes Timothy P | Officer | — | D | Stock Option (right to buy) | 2,142 | 7.70 | 16.5K | — | — | ↗ |
| 2022-08-29 | Zannes Maria | Officer | — | D | Common Stock, par value $0.007 | 0 | 0.00 | — | 3,571 | — | ↗ |
| 2022-08-29 | Rubin Gary D | Director | — | D | Stock Option (right to buy) | 7,142 | 4.20 | 30.0K | — | — | ↗ |
| 2022-08-29 | Rebel Vivienne I | Officer | — | D | Common Stock, par value $0.007 | 0 | 0.00 | — | 7,142 | — | ↗ |
| 2022-08-29 | Perlmutter Nathan M | 10% Owner | — | D | Common Stock, par value $0.007 | 0 | 0.00 | — | 166,089 | — | ↗ |
| 2022-08-29 | Meghji Mohsin Y | Director | — | D | Common Stock, par value $0.007 | 0 | 0.00 | — | 28,571 | — | ↗ |
| 2022-08-29 | KNIGHT PETER S | Director | — | D | Stock Option (right to buy) | 7,142 | 4.20 | 30.0K | — | — | ↗ |
| 2022-08-29 | GIRGENTI STEVEN | Officer | — | D | Common Stock, par value $0.007 | 0 | 0.00 | — | 249,278 | — | ↗ |
| 2022-08-29 | Edwards James Michael | Officer | — | D | Common Stock, par value $0.007 | 0 | 0.00 | — | 27,875 | — | ↗ |
| 2022-08-29 | DIAMOND STUART | Director | — | D | Stock Option (right to buy) | 7,142 | 4.20 | 30.0K | — | — | ↗ |
| 2022-08-29 | Anderson Robert A. | Director | — | D | Stock Option (right to buy) | 7,142 | 4.20 | 30.0K | — | — | ↗ |
| 2022-07-20 | Rubin Gary D | Director / 10% Owner | — | D | Warrants (right to buy) | 4,896 | 5.25 | 25.7K | 0 | — | ↗ |
| 2022-07-20 | Perlmutter Nathan M | 10% Owner | A-Award | A | Warrants (right to buy) | 47,935 | 5.25 | 251.7K | 47,935 | — | ↗ |
| 2022-07-20 | GIRGENTI STEVEN | Officer | A-Award | A | Warrants (right to buy) | 123,811 | 0.00 | — | 123,811 | — | ↗ |
| 2022-07-20 | Edwards James Michael | Officer | A-Award | A | Warrant (right to buy) | 761 | 0.00 | — | 761 | — | ↗ |
| 2021-11-22 | Joyce Roby | Director | — | I | Warrant | 14,285 | 5.25 | 75.0K | 0 | — | ↗ |
| 2021-08-26 | Reveles Xavier Trinidad | Officer | — | D | Stock Option (Right to Buy) | 2,142 | 7.70 | 16.5K | 0 | — | ↗ |
| 2017-07-11 | Rubin Gary D | Director / 10% Owner | — | I | Series A Convertible Preferred Stock | 230,309 | 5.17 | 1.19M | 0 | — | ↗ |
| 2017-07-11 | Perlmutter Nathan M | 10% Owner | — | D | Series A Convertible Preferred Stock | 103,682 | 6.75 | 699.9K | 0 | — | ↗ |
| 2017-07-11 | Meghji Mohsin Y | Director | — | D | Series A Convertible Preferred Stock | 286,349 | 3.67 | 1.05M | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-185.5K
Shares Outstanding
4.50M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Maria Zannes | Founder, President, Chief Executive Officer & Director | 369.0K | female |
| James Michael Edwards | Chief Financial Officer | 330.1K | male |
| Steven Girgenti | Founder & Executive Chairman of the Board | 167.4K | male |
| Timothy Zannes | Executive Vice President, Secretary & General Counsel | — | male |
| William Bauta | Chief Science Officer | — | — |
| Dallas J. Coleman | Vice President of sales | — | male |
| Xavier T. Reveles | Chief Operating Officer | — | male |
| Gordon Downie | Chief Medical Officer | — | — |
| Julie Anne Overton | Director of Communications | — | female |
ESG Rating
ESG Score History MEDICAL - DIAGNOSTICS & RESEARCH
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BIAF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
